Rocket Pharmaceuticals vs Soligenix
RCKT and SNGX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How RCKT and SNGX compare
Rocket Pharmaceuticals is the larger company, worth 38 times as much as Soligenix ($232M against $6.1M).
Soligenix scores higher on the StockData Score (6 against 3 for Rocket Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | RCKT | SNGX |
|---|---|---|
| Size and price | ||
| Market cap | $232M | $6.1M |
| Share price | $2.11 | $0.281 |
| Change, 1 year | −30.8% | −79.5% |
| Change, 5 years | −91.1% | −99.9% |
| Beta (5Y) | 2.32 | 2.38 |
| Employees | 202 | 14 |
| StockData Score | ||
| Total score | 3 | 6 (better) |
| Valuation score | 1 | 1 |
| Growth score | 0 | 0 |
| Performance score | 1 (better) | 0 |
| Health score | 1 | 5 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/B | 0.6× (better) | 0.9× |
| FCF yield | −73.6% | – |
| Profitability | ||
| Return on equity | −4.8% (better) | −242% |
| Return on invested capital | −180% | – |
| Financial health | ||
| Debt / equity | – | 0.00 |
| Interest coverage | −101.3× | – |
| Current ratio | 9.24 (better) | 2.77 |
| Altman Z-score | −2.72 (better) | −35.09 |
| Piotroski F-score | 1 | 3 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 90.9% | 4.3% |
| Held by insiders | 22.3% | 0.69% |
| Insider net buying, 12 months | −$934K | – |
| Short interest, % of float | 19.0% | 0.31% |
Go deeper
- RCKT stock overview
- RCKT income statement
- RCKT valuation and score
- SNGX stock overview
- SNGX income statement
- SNGX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.